The ELOVL5 (Elongation of Very Long Chain Fatty Acids 5) antibody is a research tool designed to detect and study the ELOVL5 protein, a member of the ELOVL family of enzymes critical in the elongation of polyunsaturated fatty acids (PUFAs). ELOVL5 specifically catalyzes the elongation of C18 and C20 PUFAs to form very long-chain fatty acids (VLCFAs, up to C24), which are essential components of cellular membranes, signaling molecules, and precursors for bioactive lipids. Dysregulation of ELOVL5 has been implicated in metabolic disorders, neurodegenerative diseases, and cancers, making it a target for investigating lipid metabolism pathways and disease mechanisms.
ELOVL5 antibodies are commonly used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein expression levels, localization, and tissue distribution. Studies utilizing these antibodies have revealed ELOVL5's role in hepatic lipid homeostasis, retinal function, and neuronal health. For instance, reduced ELOVL5 expression is linked to non-alcoholic fatty liver disease (NAFLD), while its overexpression in certain cancers correlates with tumor progression and poor prognosis.
The development and validation of ELOVL5 antibodies are crucial for understanding its physiological and pathological functions. Researchers also explore its potential as a biomarker or therapeutic target, particularly in metabolic syndromes and cancers. However, challenges remain in standardizing antibody specificity across experimental models, necessitating careful validation to ensure accurate detection in diverse biological contexts.